No Data
No Data
Acorda Fourth Quarter/Year End 2023 Update: Webcast/Conference Call Scheduled for April 1, 2024
Acorda Therapeutics, Inc. (NASDAQ:ACOR) today announced a webcast/conference call in conjunction with its fourth quarter and year end 2023 update and financial results for Monday, April 1 at 4:30 p.m. ET. To
Acorda Therapeutics: Biogen Ending Fampyra Collaboration
By Colin Kellaher Acorda Therapeutics will regain global commercialization rights to the multiple-sclerosis drug Fampyra after partner Biogen opted to end a license and collaboration agreement at the
Acorda Therapeutics to Regain Global Commercialization Rights to FAMPYRA by January 2025
PEARL RIVER, N.Y.--(BUSINESS WIRE)-- Acorda Therapeutics, Inc. (Nasdaq: ACOR) today announced it will regain global commercialization rights to FAMPYRA (fampridine) following a decision by Biogen to
Acorda Therapeutics, Inc.'s (NASDAQ:ACOR) Shares Bounce 53% But Its Business Still Trails The Industry
A Look Into Healthcare Sector Value Stocks
Understanding Value StocksA value stock is traditionally defined in terms of how investors in the marketplace are valuing that company's future growth prospects. Low P/E multiples are good base indica
Acorda Therapeutics, Inc. (NASDAQ:ACOR) Q3 2023 Earnings Call Transcript
No Data